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Abstracts 
Aim of the report 
This report provides a thorough analysis of the totality of globally available regulatory 
data sources on alerts, recalls and other safety information on medical devices that, until 
now, have not been systematically used by any single regulatory authority, including the 
EU. This amounts to a potential considerable neglect of potentially valuable information 
on safety-related medical device issues encountered around the world. From an EU 
regulatory perspective, this is of particular importance in case such devices are also on 
the market in the EU. However since the issues may cover a large spectrum of post-
market 'adverse events' / incidents (GHTF/SG2/N54R8:2006
1
), they may inform also 
about more general issues, even if the specific product is not on the market.  
The issues may range from medical device problems and failures that had no patient 
effects (yet), medical device problems with clear causal effects on patient/user health as 
well as adverse effects in patient/users that may be linked to the use of a given device or 
device type. Thus, such information is valuable from various perspectives by providing an 
additional data source for risk/signal detection complementing manufacturers' incident 
reports and thus providing means for early patient protection. Importantly, it could lead 
to the systematic detection of associations between specific products/product categories 
and adverse health effects and enable a better understanding of possible issues with 
materials, biocompatibility, procedure of use etc, opening ultimately possibilities to 
assess, in a more systematic manner, specific adverse health-effect pathways, thus 
leading to improved design ('safety-by-design' concept). 
With regard to data types, the report focuses on alerts and recalls, as provided by the 
official websites of thirteen non-EU regulatory authorities. Thus, in contrast to the JRC's 
MediSys analysis tool which searches and monitors only media reports on medical 
devices, this report addresses curated information, i.e. which has been thoroughly 
assessed and approved for publication by official bodies.  
The identified sources (webpages) and data types have been deeply analysed and 
described.  
Moreover, during a period of six weeks, all alerts and recalls from the identified sources 
have been compiled and listed in tabular format (see supplementary material). This 
compilation can serve as a basis further work in view of exploring the most effective 
ways to use, in the context of vigilance and market surveillance activities, this 
information to detect safety problems in the EU territory and prevent or promptly react to 
them. 
The analysis conducted in this report addresses the following key questions:  
1. Are the terminology and format used worldwide sufficiently targeted and 
adequate to allow for effective analysis of information and detection of signals? 
2. What are the benefits and added value of automated collection and display of 
globally available safety information for patient safety in the EU? Would it support 
the systematic use of such information? 
3. Is automated collection of such information technically feasible? This 
would include intra- and extra EU alerts, recalls and other safety communications 
(e.g. Field Safety Notices and Incident Reports)  
4. What are the technical tools that are required to create an effective functional 
system for automated and systematic collection, translation and preliminary 
analysis of global safety data? 
 
                                           
1 Medical Devices Post Market Surveillance: Global Guidance for Adverse Event Reporting for Medical Devices. 
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Key findings  
The report sets the framework of existing sources of alerts and recalls occurred in some 
of the most relevant markets of medical devices worldwide.  
In particular, it describes these sources and outlines the main differences regarding the 
information they provide. 
The report is complemented by a quantitative and qualitative analysis of real cases of 
global alerts and recalls collected over a six week period from official websites of selected 
regulatory authorities.  
This compilation includes inputs and suggestions for further discussion regarding the 
potential value and usefulness of the information. 
In this respect, the report shows a number of important issues relating to four key areas: 
1. Data set 
The amount of available data relating to alerts, recalls and other safety relevant 
communications is considerable.  
Importantly, the terminology used by the different regulators to label specific pieces of 
information is not fully harmonised. 
Furthermore, the information provided by the relevant authorities is displayed in 
fragmented ways, ranging from simple lists to structured databases.  
 
2. IT and translation tools  
The data to be retrieved throughout the different sources showed to be extensive, 
complex, fragmented, and of multilingual nature.  
In light of this, specific IT tools in support of effective collection, analysis and display 
of information seem to be needed.  
This includes translation tools from various languages into English, means of checking 
the identity of a given entity (e.g. company) etc. 
 
3. Relevance of existing data for the EU 
Only one of the analysed sources (i.e. FDA website) provides the list of countries 
(including EU members) where the given product affected by a safety issue is 
circulated on the market. 
The information regarding the presence on the Union market of safety measures 
occurred outside Europe is key for EU CAs to timely react to possible problems in the 
EU.  
However, even in case the devices is not on the market, the safety issue may point to 
flaw or failure relating to issues such as materials, biocompatibility or procedure which 
may be applicable to other devices and hence provide early warnings with regard to 
possible imminent safety issues. 
 
4. Practical working procedure for data management  
Globally available data on alerts and recalls and other safety relevant communications 
are not systematically and appropriately shared.  
In order for the EU to take advantage of their potential, Member State (MS) CAs 
should ensure effective coordination and full share of similar information.  
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The report finally provides, as supplementary material, a data compilation of alerts and 
recalls collected during a six-week scoping exercise. 
This activity was mainly conducted to provide relevant actors (e.g. EU CAs, Commission, 
other extra-EU regulators) with a real picture of the amount and type of global 
information which a regular monitoring activity could provide. The results of the scoping 
exercise are intended to serve as a basis for the identification of key issues relating to 
the management and exploitation of global alerts and recalls.  
However, the results would be highly relevant for discussions at the level of the 
International Medical Device Regulators Forum: the implementation of one single tool 
that collects and displays globally available curated safety information (including from 
EU) and provides an English translation as well as an entity check, would support 
competent authorities worldwide and facilitate their cooperation in view of market 




This report provides a comprehensive overview of additional official sources of 
information made publicly available by thirteen regulatory authorities responsible for 
vigilance of medical devices2 outside the European Union, as provided through their 
governmental websites.  
In particular, the document outlines and describes these extra EU sources of information 
(with a special focus on alerts and recalls) and stresses the important role that these 
data could play in support of the EU CAs for early detection of safety problems (signals) 
with medical devices in Europe.  
In order to benefit from this key information, it will be of utmost importance to use it in a 
systematic way that allows identifying the relevance of the collected extra EU alerts and 
recalls for European territory, including the case when the concerned products are not 
placed on the Union market.  
In order to establish a complete framework of the available safety communications, the 
report also contains a description of information other than alerts and recalls, such as 
Field Safety Notices (FSNs) and incident reports.  
The analysis covers all the members3 of the International Medical Device Regulators 
Forum (IMDRF), except from the EU; in order to ensure geographic balance between the 
different regions of the world, this report also takes into account five of the biggest and 
most representative medical devices' markets among the non-IMDRF countries4.  
The set of information described and analysed in this report is part of the effort of the 
Joint Research Centre (JRC) to facilitate the identification of means for a strengthened 
vigilance and market surveillance activity of the European Union in the field of medical 
devices. This may include a management tool for the systematic collection and 
preliminary analysis of globally available safety information for possible signal detection 
in the EU. With MediSys the JRC has already installed a tool for monitoring international 
media reports on medical devices. This could, in the future, be complemented by a tool 
for collecting regulatory information on alerts and recalls.  
                                           
2 The term medical device is meant to include also in vitro diagnostics and active implantable medical devices. 
3 AUSTRALIA-Therapeutic Goods Administration, BRAZIL-Brazilian Health Surveillance Agency, CANADA-Health 
Canada, CHINA-China Food and Drug Administration, JAPAN-Pharmaceuticals and Medical Devices Agency, 
RUSSIA-Federal Service on Surveillance in Healthcare and Social Development, USA-Food and Drug 
Administration. 
4 ARGENTINA-National Administration of Drugs, Food and Medical Devices, MEXICO-Federal Commission for the 
Protection against Sanitary Risks, NIGERIA-National Agency for Food and Drug Administration and Control, 
SAUDI ARABIA-Saudi Food and Drug Authority, SOUTH AFRICA-Department of Health. 
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2 A possible work procedure for the management of extra 
EU safety information: the NCAR exchange framework 
The large amount of safety information available globally poses the issue of its regular 
monitoring and good management. It is therefore very important for the EU CAs to set 
up a system allowing for effective use and share of all collected extra EU safety 
information. 
At EU level, the Competent Authorities for medical devices have put in place a working 
procedure to analyse safety problems occurred in the their territory and exchange views 
regarding the actions needed.  
This procedure is based on monthly teleconferences that are coordinated by the 
Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG 
GROW) of European Commission in the framework of the activities of its Medical Devices 
Expert Group (MDEG) on Vigilance. 
These teleconferences focus on the analysis of information on adverse events as 
disseminated through the National Competent Authority Reports (NCARs).  
The information contained in the NCARs as well as the extra EU alerts and recalls fall in 
the vigilance/market surveillance area and both require a prompt and coordinated 
reaction by the EU Competent Authorities.  
Therefore, the work procedure based on monthly teleconferences already applied to 
NCARs could possibly be expanded to extra EU alerts and recalls. 
A coordinated management of this information would contribute to the improvement of 
the protection of health and safety of patients by reducing the likelihood of recurrence of 
incidents and preventing their repetition through the adoption of appropriate and 
concerted field safety corrective actions.  
It is to be noted that this activity is closely related to the NCAR Exchange Program 
established by the Global Harmonisation Task Force (GHTF5) and currently being 
reviewed by the IMDRF.  
Following the NCAR Exchange Program, 29 regulators committed to exchange 
confidential information on adverse events with regard to medical devices with global 
distribution.   
The NCAR Exchange Program and the information shared at international level should 
therefore be taken into account by the EU CAs when analysing extra EU safety data. 
                                           
5 The ‘Global Harmonization Task Force (GHTF)’ is a voluntary international group of representatives from 
medical device regulatory authorities and trade associations from Europe, the United States of America (USA), 
Canada, Japan and Australia. GHTF was conceived in 1992 in an effort to respond to the growing need for 
international harmonisation in the regulation of medical devices. The GHTF mission ended in December 2012. 
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3 Analysis of publicly available sources of alerts, recalls and 
other relevant information 
This section illustrates and describes the sources of information on alerts, recalls and 
other safety relevant information made available, through their official websites, by 
thirteen regulators in different regions of the world (See Chapter 1).  
Although focusing on alerts and recalls, the report also takes into account other safety 
information potentially relevant for early detection of risks, problems or incidents with 
medical devices in the EU.  
The review of the different sources of information showed that, the terminology used and 
the description provided by the different regulatory authorities to identify alerts, recalls 
and other warning information are quite heterogeneous. 
It is, therefore, important to reflect on the development of an internationally harmonised 
"language" for the description of safety measures.  
Future possible changes of the state of play of the sources relating to the jurisdictions 
covered by this report will be closely monitored and regular updates will be introduced, 
as needed.  
In the same way, additional relevant regions of the world may be taken into account in 
the future.  
 
3.1 IMDRF members 
 
3.1.1 AUSTRALIA - Therapeutic Goods Administration   
The Therapeutic Goods Administration (TGA6) is part of the Australian Government 
Department of Health and Ageing, and is responsible for regulating therapeutic goods 
including medicines, medical devices and in vitro diagnostics, blood and blood products. 
Before being supplied in Australia, therapeutic goods, including contents and 
classification details, are registered by TGA in the Australian Register of Therapeutic 
Goods (ARTG7) database.  
The official webpage of the TGA includes a specific section called "safety information" 
which provides information on current and historic recalls of medicines and medical 
devices, advice issued by TGA about products, monitoring communications, information 
on reporting problems and how the safety of therapeutic products is monitored. 
TGA provides a service for automatic safety information updates that can be activated 
through the following sections of its website:  
 "Medical Devices Safety Update email list" (system notifying subscribers when the 
latest version of the Medical Devices Safety Update is available on the TGA website, 
 "Safety Information email list" (system notifying subscribers when new alerts, recalls 
and advisory statements are published on the TGA website). 
The information provided by this section of the TGA webpage is divided into the following 
sections. 
 Recalls  
Recalls are conceived as those actions taken to resolve a safety, quality, efficacy or 
presentation problem or deficiency with a device already supplied in the market.  
                                           
6 https://www.tga.gov.au/.  
7 https://www.tga.gov.au/searching-australian-register-therapeutic-goods-artg.  
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Recall actions are grouped into the following three categories: 
 Recall - permanent removal of an affected device from supply or use in the market, 
 Recall for product correction - device repair, modification, adjustment or re-labelling,  
 Hazard alert - information issued to healthcare professionals about problems occurred 
to implanted device or biological product and advice about patients' management. 
Recall actions are classified based on the potential risk posed by the deficiency to 
patients/consumers according to the following three classes: 
 Class I recall - product deficiency is potentially life-threatening or could cause a 
serious risk to health, 
 Class II recall - product deficiency could cause illness, injury or result in mistreatment, 
 Class III recall - product deficiency may not pose a significant hazard to health, but 
other reasons could justify actions (e.g. quality related issues). 
A summary of recent recall actions, from 1 July 2012, are contained in the System for 
Australian Recall Actions (SARA) database.  
 Alerts 
Alerts explain the outcome of an investigation, including recommendations for consumers 
and health professionals, a change to the availability of a product, or advise about 
detection of counterfeit or illegal products. The safety information section of the TGA 
website contains all alerts issued since 1998.  
 Early warning system  
This Early Warning System provides current and historical information on safety concerns 
identified by the TGA vigilance program: 
a. Monitoring communications - Early communications about potential safety concerns 
which have not been fully investigated to highlight potential safety concerns that are 
identified by the TGA. It is to be noted that, following a monitoring communication, 
consumers should not stop using a device, health professionals should not change 
patient's treatment and not all of these concerns will result in actions, in particular when 
no link between the events and the product can be established. This section contains 
communications since 2013. 
b. Alert communications - Alert communications are issued after a safety concern having 
been investigated. Alerts contain more information on the safety concerns and provide 
advice on actions that may need to be taken by health professionals and consumers. 
Safety concerns may result in a recall action (removal of the product or corrective 
action), especially when a defective device is identified.  
 Reporting problems with MD 
The TGA's Incident Reporting and Investigation Scheme (IRIS8) focuses on adverse 
events or incidents related to the use of medical devices and is based on investigations of 
adverse events or potential adverse events' reports from devices' users that can lead to 
actions such as product recalls, safety alerts, product improvement, user education and 
compliance testing. Adverse events can be reported manually or following specific online 
forms by device users (clinicians, patients or their relatives) and/or MFRs/sponsors. Once 
introduced, the report will be investigated and discussed with the manufacturer/supplier 
and, if TGA considers that an action is needed, it may involve any of the following: 
 Recall - removal or corrective measure due to safety, performance or quality reasons, 
 Safety Alert - distribution of urgent information to the responsible for the device, 
 An alert or advisory notice - general information through the website. 
                                           
8 https://www.tga.gov.au/medical-device-incident-reporting-investigation-scheme-iris.  
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Medical device incident reporting & investigation scheme (IRIS) 
IRIS is the tool used by TGA to manage the medical devices' reports of adverse events or 
problems as received from consumers, health professionals and industry.  
These reports received either manually or automatically, are then collected in a database 
after correctness and completeness being checked by TGA. 
Adverse events reports are classified on a risk basis and actions are taken following a risk 
assessment analysis. The actions can include: 
Informing health professionals and consumers through alerts and articles on the TGA’s 
website and other publications, 
 Request for product improvement or for changes to IFU9 or labelling (e.g. warnings), 
 Product recall from the market, 
 Withdrawal of product market approval or restriction of use, 
 Request for additional user education, 
 Request for quality inspections, 
 No request for actions but regular monitoring for trends' identification. 
Safety information & education 
The "Safety information" section of the TGA webpage provides links to articles about the 
general safety of medicines and medical devices and allows accessing the medical 
devices Database of Adverse Event Notifications (DAEN10) database which provides 
information about adverse events related to medical devices in Australia.  
 
3.1.2 BRAZIL - Brazilian Health Surveillance Agency  
The National Health Surveillance Agency (ANVISA11) is the regulatory agency of the 
Brazilian Ministry of Health which has as its main goal the protection and promotion of 
public health. To this aim, ANVISA conducts vigilance and market surveillance activities 
in several areas such as drugs, food, cosmetics, and medical devices.  
In this respect, the ANVISA website includes two sections providing information on alerts 
(Alertas sobre produtos para a saúde) and reports on health products (Informes sobre 
produtos para saúde). 
It is to be noted that, with the exception of a general introduction provided in English, 
the ANVISA website is in Portuguese only. 
 
3.1.3 CANADA - Health Canada  
Health Canada is the Federal department responsible for medical devices through its 
Therapeutic Products Directorate12 (TPD) which is in charge of conducting the pre-market 
assessment of medical devices' safety, effectiveness and quality ensuring as well post-
approval surveillance and quality systems in the manufacturing process.  
The department routinely evaluates Canadian adverse event reports and, in case safety 
issues are identified, takes appropriate actions such as distribution of new product safety 
information, recommendation of changes to the product's labelling or request for product 
removal from the market. 
                                           
9 Instructions for use. 
10 https://www.tga.gov.au/database-adverse-event-notifications-daen. 
11 http://portal .anvisa.gov.br/     
12 http://www.hc-sc.gc.ca/ahc-asc/branch-dirgen/hpfb-dgpsa/tpd-dpt/index-eng.php.  
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 Recalls and Safety Alerts Database 
In addition, the Health Canada's Marketed Health Products Directorate (MHPD) has 
developed the MedEffect program to improve the safety, effectiveness and access to 
therapeutic products available. Through the MedEffect webpage it is possible to have 
access to a link to the Recalls and Safety Alerts Database that provides access to recalls, 
advisories, and safety alerts, including a newsletter with information about adverse 
events.  
The Recalls and Safety Alerts Database includes safety alerts and recalls of different 
products (food, consumer products, vehicles and health products), however, the 
database search engine allows conducting targeted searches specific to medical devices.  
 Health Product Info Watch 
Among the different sources of information on safety related problems, it is to be 
mentioned the Health Product Info Watch.  
It is a newsletter providing information on serious or unexpected side effects or adverse 
reactions suspected of being associated with health products, such as medical devices, to 
make people aware about safety issues with health products.  
The newsletter also alerts about signals related safety issues detected during reviews of 
suspected adverse reaction cases, which are reported to Health Canada through the 
Canada Vigilance Program and the Mandatory Problem Reporting for Medical Devices.  
 Canada Vigilance Adverse Reaction Database 
Since 1965, the Canada Vigilance Program collects and assesses reports of suspected 
adverse reactions to health products, including medical devices, which can be accessed 
through the Canada Vigilance Adverse Reaction Online Database. 
 Summary Basis of Decision documents: Medical Devices 
The Health Canada web page provides access to the Summary Basis of Decision SBD 
documents that explain why Health Canada authorized certain MDs and IVDs for sale in 
Canada.  
The documents include regulatory, safety, effectiveness and quality (manufacturing) 
considerations. 
 
3.1.4 CHINA - China Food and Drug Administration   
The China Food and Drug Administration (CFDA13) is the body responsible for the medical 
devices' legislation and its implementation, including market surveillance and vigilance. 
In order to carry out these activities, the CFDA is structured around two main 
departments dealing with medical devices: 
 Department of Registration, 
 Department of Supervision. 
Apart from a specific section on the laws and regulations regulating the medical devices, 
no other information is provided through the English version of the CFDA official website. 
On the opposite, the Chinese version appears to be much wider and could potentially 
include data on alerts and recalls and other related safety measures.  
 
                                           
13 http://eng.sfda.gov.cn/WS03/CL0755/.  
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3.1.5 JAPAN - Pharmaceuticals and Medical Devices Agency  
The Pharmaceuticals and Medical Devices Agency (PMDA14) is the Japanese regulatory 
body responsible to ensure the safety, efficacy and quality of medical devices.  
The official website of the PMDA is an important source of information on recalls, alerts 
and other safety information as provided by the Japanese Marketing Authorization 
Holders (MAH) when a product that they have marketed might cause a hazard associated 
with the use of medical devices. 
 "Yellow Letter" and "Blue letter" 
This section of the PMDA website includes the communications to be provided by the 
marketing authorisation holders to healthcare professionals by means of the so called 
"Yellow Letter" (Dear Healthcare Professional Letters of Emergent Safety 
Communications) and "Blue Letter" (Dear Healthcare Professional Letters of Rapid Safety 
Communications). 
These letters are sent in cases where medical devices might cause hazards to patients, 
and measures need to be taken, including recall, suspension of sales, and information 
provision to prevent such hazards. 
The Yellow Letter contains emergent and important medical devices' safety information. 
The Blue Letter contains information that does not require emergent communications as 
Yellow Letter but should be promptly provided to alert healthcare professionals. 
It is to be noted that this information is not always provided in English. 
 MHLW Pharmaceuticals and Medical Devices Safety Information 
This section includes safety information collected by the Ministry of Health, Labour and 
Welfare (MHLW) to facilitate healthcare professionals when using medical devices.The 
English version of this section is for information purpose only and, in order to have a 
complete overview of all related data it is necessary to consult the Japanese version, 
which also prevails in case of inconsistency with the information provided in English. 
 Revisions of PRECAUTIONS 
This section includes notices to revise the precautions (warning, contraindications and 
adverse reactions/events) in product inserts. The notices are issued MHLW following a 
recommendation by PMDA.  
It is to be noted that this information is available in English. 
 Notification on self-check 
This section of the PMDA website contains MHLW's recommendations addressed to the 
marketing authorization holder to conduct self-check relating to the proper use of 
medical devices and, if needed, to adopt the needed revisions of the package inserts or 
user manuals. The English version of this section is for information purpose only and, in 
order to consult all related data it is necessary to consult the Japanese version, which 
also prevails in case of inconsistency with the information provided in English. 
 PMDA Medical Safety Information 
"PMDA Medical Safety Information" section of the PMDA website includes the information 
analysed in the previous paragraphs in a more understandable and widely disseminated 
way, including data on medical incident reports, reporting of similar events, cases leading 
to notifications for revisions to package inserts and recommendations on a safe use of 
devices. 
It is to be noted that, although this information being available in English, the Japanese 
version prevails. 
                                           
14 http://www.pmda.go.jp/english/about-pmda/index.html.  
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3.1.6 SINGAPORE - Health Sciences Authority  
The Singapore Health Sciences Authority (HSA) is structured into three main groups 
through which it carries out its mission. In particular, the Health Products Regulation 
Groups manages the regulatory framework on biomedical products which is responsible 
for medical devices and ensures that they meet appropriate safety, quality and efficacy 
standards. All information regarding medical devices registered in Singapore for use in 
human being under the Health Product Act (Medical Device Regulation) are made publicly 
available online through the Singapore Medical Device Register (SMDR) database.  
HSA Vigilance/Post-market surveillance 
Field Safety Corrective Action  
As part of its vigilance post-market surveillance, HSA runs a system for the collection and 
share of Field Safety Corrective Actions (FSCA) in order to ensure safety of medical 
devices suspected of being potentially harmful to users, due to nonconformity to quality, 
safety and performance requirements. To this aim, all information on FSCA relating to 
both devices manufactured or supplied in Singapore and to devices that, although not 
supplied in Singapore, have marketing authorisation or have been imported in the 
country, must be reported to HAS according to specific guidelines and forms. These 
actions can include the removal of medical devices from the market or any other 
corrective action on devices in use. Usually, they are preceded by a Field Safety Notice 
(FSN) of the product owner (alternatively the registrant or importer) to inform operators 
and users regarding risks of medical devices and to advise about the measures to be 
taken in order to protect the health or the safety of patients, users or other persons. Also 
FSNs are made publicly available by HAS. 
Adverse Event Reporting 
In addition to FSCAs and FSNs, in order to ensure effective post-market surveillance and 
continued safe use of devices, HSA established a series of requirements including 
reporting of adverse events from healthcare professionals, mandatory reporting from 
manufacturers and dealers, and exchange of regulatory information with other medical 
device regulatory agencies. The report is to be submitted upon request of HSA. Specific 
guidelines and forms are established by HSA for each of the different kind of reporting. 
The adverse events to be reported are classified according to three main reporting 
criteria: 
1. An adverse event (or potential adverse event) has occurred, 
2. The device product is associated with the adverse event, 
3. The adverse event led to one of the following outcomes: 
 Serious threat to public health; 
 Death of a patient, user or other person; 
 Serious deterioration in state of health of patient, user or other person; 
 No death or serious injury occurred but the event might lead to death or serious  
 Injury of a patient, user or other person if the event recurs. 
The reporting timeline for adverse event reporting for dealers of device products are: 
 Within 48 hours for events that represents a serious threat to public health; 
 Within 10 days for events that has led to the death, or a serious deterioration in the  
 State of health, of a patient, a user of the medical device or any other person; 
 Within 30 days for events where a recurrence of which might lead to the death, or a  
 Serious deterioration in the state of health, of a patient, a user of the medical device 
or any other person 
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Once the reports are received, HSA reviews them, conducts trend analysis and, if 
unexpected adverse effects are identified through the adverse event report, this can 
determine changes such as refinement of instruction of use or introduction of specific 
warnings. In case a hazard is considered unacceptable, the device could also be 
withdrawn from the market. 
Safety Information on medical devices 
The safety information section of the HSA website includes a series of information on 
enforcement, post-market vigilance and compliance activities of the HSA Authority, as 
well as product safety information and recalls. 
As specifically regards medical devices, under this section it is possible to find alerts, 
safety messages (Product Safety Alerts), letters to healthcare professionals (Dear 
Healthcare Professional Letters), recalls, and label amendments (Safety-related Product 
Label Amendments). 
Medical Device Alerts 
As part of the HSA’s post-market safety surveillance programme for medical devices, this 
website provides information on medical device safety issues or events in order to raise 
awareness amongst healthcare professionals.  
In addition, it aims at encouraging reporting of adverse events by physicians, dentists 
and pharmacists. 
Product Safety Alerts 
This website provides safety messages on drugs, medical devices and related health 
products which have major impact on public health and safety.  
Dear Healthcare Professional Letters 
This website provides the abstracts of the Dear Healthcare Professional Letters (DHCPL), 
which are advisory letters to healthcare professionals by HSA, pharmaceuticals and 
medical device companies. For more details regarding the DHCPL, it is important to refer 
to the Health Professional Portal (HPP) of the Ministry of Health (MoH) Alert System 
(http://www.hpp.moh.gov.sg/).   
Safety-related Product Label Amendments 
This website provides information on labelling amendments made to the local package 
inserts.  
Product Recalls    
This website provides a list of products recalled by HSA as part of the Product Quality 
Surveillance programme. While not being an exhaustive list of all health products that 
could be the subject of a recall, the aim of this information is to alert consumers and 
healthcare professionals on some of the past recalls of health products in Singapore. 
 
3.1.7 RUSSIA - Federal Service on Surveillance in Healthcare and Social 
Development  
The Federal Service on Surveillance in Healthcare and Social Development (FSSHSD15) is 
the body of the Ministry of Health and Social development of Russian Federation 
responsible for the implementation of the Russian legislation on medical devices and 
drugs.  
As regards alerts and recalls and other safety related information, although the Russian 
version of the FSSHSD website appears to provide this information, the English version 
only provides a general introduction to the different sections of the website.  
                                           
15 http://www.roszdravnadzor.ru/.  
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3.1.8 USA - Food and Drug Administration  
The Food and Drug Administration (FDA16) is the United States' national regulatory 
agency responsible for the medical devices' safety. 
The FDA official website provides different kinds of information relating to the safety of 
medical devices which are divided in two main areas: i) Medical Device Safety and ii) 
Medical Device Ban.  
The first area includes safety communications and medical device recalls while the 
second area provides information on post market surveillance measures, reporting of 
medical devices' problems, adverse events and news. 
 Medical Device Safety 
Safety Communications  
In this section, the FDA publishes communications addressed to consumers, health care 
providers, businesses and all other potential users of a specific device to alert about its 
malfunctioning (e.g. ineffective delivery system, chemical reactions) or about the risks 
relating to the use of the device and its characteristics.  
The alerts contain information that may determine actions impacting both treatment and 
diagnostic choices for healthcare professional and patient. Therefore, the purposes of 
these communications can be different and go from risk awareness rising to suggestion 
of better techniques for safe use or recommendation against its use of a product.  
The FDA issues such alerts after knowing about a problem with a device and this usually 
happens because FDA receives complaints and reports on adverse events or problems 
with the use of a device. Subsequently, verification such as an inspection of the relevant 
company's facility is conducted by the FDA to verify the problem at stake. 
"MedWatch" is the FDA online tool giving access to the list of safety alerts.   
Medical Device Recalls  
This page of the FDA official website is dedicated to recalls of medical devices for which 
there is a reasonable chance that they could cause serious health problems or death. 
In order to consult recalls relating to Class I and some Class II and III recalls it is 
possible to refer to the yearly lists of 2014, 2015 and 2016 whose the link is placed on 
the top left of the page. The list relating to 2013 is archived and the link is placed on the 
top right of the page. 
The full list of Class II and III recalls is made available by the CDRH Recalls Database.  
Adverse Event Reporting – Voluntary reporters  
MedWatch also allows consumers or healthcare professionals voluntarily reporting 
significant adverse events or product problems with medical products to FDA. 
In particular, through MedWatch consumers and healthcare professionals report serious 
adverse event, product quality problem, product use error, or failure associated with the 
use of a medical device. Suspected counterfeit medical products can also be reported to 
FDA through MedWatch.  
Adverse events reporting system – Mandatory reporters 
Reporting of medical adverse events is made mandatory for manufacturers, importers 
and user facilities (e.g., hospitals, nursing homes) through the Medical Device Reporting 
regulation (21 CFR 803) which sets the following reporting requirements: 
                                           
16 http://www.fda.gov/default.htm.  
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• Manufacturers:  - to report to FDA when one of their devices may have caused or  
  contributed to a death or serious injury, 
 - to report to FDA when one of their devices has malfunctioned and  
  would be likely to cause or contribute to a death or serious injury if  
  the malfunction happened again; 
• Importers:  - to report to FDA and the manufacturer when one of their devices  
  may have caused or contributed to a death or serious injury, 
 - to report only to the manufacturer when one of their devices has  
  malfunctioned and would be likely to cause or contribute to a death or  
  serious injury if the malfunction were to happen again; 
• User Facilities:  - to report suspected medical device-related death to both the FDA  
  and the manufacturer,  
   - to report a medical device-related serious injury only to the  
   manufacturer, if known, otherwise to FDA. 
Although not being obliged to do it, for the reporting of a malfunction or problems with 
medical devices user facilities can voluntarily use the MedWatch program to advise FDA.  
Manufacturers and User Facility Device Experience Database 
The Manufacture and User Facility Device Experience (MAUDE) database hosts the 
Medical Device Reports (MDRs) submitted to the FDA by mandatory reporters 
(manufacturers, importers and device user facilities) and voluntary reporters such as 
health care professionals, patients and consumers.  
The reports include a brief description of the incident, with information about the device, 
manufacturer and the type of reporter. These reports, which refer to suspected device-
associated deaths, serious injuries and malfunctions, are used by the FDA to monitor 
device performance, detect potential device-related safety issues, and contribute to 
benefit-risk assessments. The MAUDE searchable database data contains the last 10 
year's data and allows searching the FDA’s Center for Devices and Radiological Health 
(CDRH). MAUDE database is updated monthly and the search page reflects the date of 
the most recent update. 
Although being very useful for vigilance purposes, these reports present several 
limitations mainly due to their passive nature that could have an impact on the 
completeness, accuracy, MDR data alone cannot be used to establish rates of events 
evaluate a change in event rates over time or compare event rates between devices. The 
number of reports cannot be interpreted or used in isolation to reach conclusions about 
the existence, severity, or frequency of problems associated with devices. In this respect, 
it should be taken into account that confirming whether a device caused a specific event 
can be difficult if based only on information provided in a given report and further 
verification of the circumstances surrounding the event or direct evaluation of the device 
could be needed.  
It is also to be considered that safety information for a reported medical device should be 
interpreted in the context of other available information when taking decisions. Moreover, 
certain types of information contained in the reports are protected from public disclosure 
under the Freedom of Information Act (FOIA). 
The FDA's Sentinel Initiative 
The Sentinel Initiative is an FDA ongoing project aimed at developing an electronic 
system, complementing existing systems, to track adverse events of drugs, biologics, 
and medical devices on the market. The Sentinel System is based on a proactive 
approach, also known as active surveillance, through which the FDA actively queries 
diverse automated healthcare data sources such as health record systems, administrative 
and insurance claims databases, and registries to evaluate possible safety issues quickly 
and securely. 
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The FDA will therefore be able to actively request information from the Sentinel System 
data partners (e.g. academic medical centres and healthcare systems) when a safety 
question arises about a product. This proactive initiative complements the passive 
surveillance safety systems, such as MAUDE, currently in use by FDA, enabling the FDA 
to use existing electronic healthcare  
The Sentinel Initiative has been launched in 2008 and is now being tested through a pilot 
project called "Mini Sentinel". 
Medical Product Safety Network 
The Medical Product Safety Network (MedSun) is an adverse event reporting program 
launched in 2002 by the FDA Centre for Devices and Radiological Health (CDRH) 
according to which a network of approximately 250 hospitals, nursing homes, and home 
health facilities, are required to report medical device problems that result in serious 
illness, injury, or death.  
MedSun participants are also encouraged to voluntarily report problems with devices, 
such as ‘close-calls,’ potential for harm, and other safety concerns. This database collects 
reports with a brief description of adverse events related to devices.  
As part of the MedSun network program, it is also to be mentioned the MedSun 
Newsletter containing information on newly approved devices, links to FDA/CDRH 
databases and other information sources and update list of recalls and safety alerts. 
Medical Device Reporting database 
The Medical Device Reporting (MDR) database allows you to search the CDRH's (Centre 
for Devices and Radiological Health) database information on devices which may have 
malfunctioned or caused a death or serious injury during the years 1992 through 1996.   
The files contain reports received under both the mandatory Medical Device Reporting 
Program from 1984 to 1996, and the voluntary reports up to June 1993. The database 
currently contains over 600,000 reports.  
The reports include a description of the adverse event, and information about the device 
and manufacturer.  
It is no longer being updated, MDR after 1996 are included in MAUDE Database.  
 Medical Device Ban 
This section of the FDA website regards those medical devices for which a ban has been 
declared, meaning that current and future sales, distribution, and manufacturing of the 
concerned devices are totally prohibited. 
The decision of the FDA to adopt such a measure, which is very rare (only one till now17), 
is based on available data and information proving that the device presents a substantial 
deception to patients or users about the benefits of the device (risk-benefit analysis), or 
an unreasonable and substantial risk of illness or injury, which cannot be corrected by a 
change in the labelling.  
In order to determine that a device is deceptive, the FDA considers whether users may 
be deceived or otherwise harmed by the device itself and the ban can be decided even in 
the absence of proof of illness or injury.  
Once a regulation to ban a device is published in the Federal Register, the product can no 
longer be legally marketed except under an approved investigational device exemption.  
                                           
17 Prosthetic hair fibers - Decision Effective from June 3, 1983.  
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3.2 Non-IMDRF members 
3.2.1 ARGENTINA – National Administration of Drugs, Food and Medical 
Devices 
The National Administration of Drugs, Foods and Medical Devices (ANMAT) is the medical 
devices' regulatory authority of the Argentinian Ministry of Health.  
In particular, ANMAT is responsible for the authorization, registration, standardization, 
and vigilance and monitoring of devices with the specific purpose of ensuring their 
compliance with efficacy, safety and quality requirements. 
 Techno-vigilance Program 
As regards the vigilance area, the ANMAT developed a techno-vigilance program aimed to 
collect, assess and manage medical devices' adverse events and carry out the most 
appropriate corrective actions, as needed.  
This program achieves the early detection of adverse and/or unexpected events and also 
performance fails in the stage of widespread use.  
The techno-vigilance dedicated page of the ANMAT website includes a form used to notify 
adverse events or technical fails with MD.  
These notifications are assessed by a consultant committee composed of academic 
representatives, medical national associations and recognised professionals. 
When it is proved a MD causing an adverse event, appropriate actions to prevent, reduce 
and eliminate the risk for the health are taken.  
These actions can be modifications in the register of the product, in the instructions of 
use, manual of use, manufacturing, importing or commercialization suspension and also 
register withdrawn. 
The notified adverse events are also included into a non-publicly available database to 
perform trend analysis.  
Alerts and Recalls 
With specific reference to medical devices' safety related information, the ANMAT website 
contains a section, "Alerts and Recalls of Medical Devices" where alerts and recalls are 
publicly available. Up to date two alerts are published, one of 20 March 2015 and the 
other of 5 February 2016. 
The ANMAT website also includes a section on products for which a "Prohibition of use 
and/or marketing" has been issued due to regulatory irregularities in the 
manufacturing/marketing process. 
Press and communication 
As part of the sources of information, it is to be mentioned the section on "Press and 
Communication" which includes recent safety notices, alerts, articles on safety issues, 
technical information documents and scientific publications. 
 
3.2.2 MEXICO – Federal Commission for the Protection against Sanitary 
Risks  
The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) is the 
Mexican body responsible for the protection of the population against sanitary risks, 
through sanitary regulation, control and promotion.  
In the medical devices field, the COFEPRIS is in charge of ensuring high quality, 
effectiveness and safety of these products. 
17 
Alerts 
As regards the sources of information on alerts or other safety related information on 
medical devices, the COFEPRIS website includes a webpage dedicated to alerts covering 
tobacco, health services, food and dietary supplements, drugs and health consumable 
goods and other products and services.  
No specific section on medical devices is available.  
The COFEPRIS website provides information in Spanish only. 
 
3.2.3 NIGERIA - National Agency for Food and Drug Administration and 
Control  
The National Agency for Food and Drug Administration and Control (NAFDAC) is the 
Nigerian Agency responsible for regulating and controlling the manufacture, importation, 
exportation, advertisement, distribution, sale and use of food, drugs, cosmetics, 
chemicals and packaged water, and medical devices.  
Alerts and recalls 
A specific section of the NAFDAC website is dedicated to medical devices where it is 
possible to consult recently published alerts and recalls of medical devices. At the 
moment, only 4 measures taken from 13 to 17 May 2016 are visible. 
However, under the section "Publications" of the website it is possible to consult the 
archive where alerts and recalls relating to medical devices are available along with 
drugs, cosmetics, food and other products.  
All information is provided in English. 
 
3.2.4 SAUDI ARABIA - Saudi Food and Drug Authority  
The Saudi Food & Drug Authority (SFDA) is the Saudi regulatory authority for food, drugs 
and medical devices. The main purpose of the SFDA is to regulate, oversee, and control 
food, drug, medical devices, as well as to set mandatory standard specifications thereof, 
whether they are imported or locally manufactured.  
As specifically regards medical devices, the SFDA set up the National Centre for Medical 
Devices Reporting (NCMDR) to ensure safety of medical devices and to protect patients 
and public from deficient products.  
The NCMDR maintains an up-to-date database of medical-devices recalls and adverse 
event reports and supports hospitals and healthcare providers to take appropriate 
corrective actions, whereas needed.  
The National Centre for Medical Devices Reporting (NCMDRC) 
NCMDRC treats reports and feedback information about both malfunctions and suspected 
adverse events and confirmed recalls from hospitals and healthcare facilities all around 
the Saudi Arabia Kingdom.  
Once received, these reports are analysed by the SFDA in collaboration with 
manufacturers and suppliers in order to identify the best action to be taken in view of 
ensuring that the concerned product performs safely. 
The centre also collects Fields Safety Notices (FSNs) and recalls from healthcare facilities 
as well as manufacturers as published by both the SFDA and other MD Competent 
Authorities abroad (UK-MHRA, US-FDA, DE-BfArM, IE-HPRA, Hong Kong-MDCO, EU 
National Competent Authority Reports-NCARs, CH-Swissmedic and AUS-TGA). 
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3.2.5 SOUTH AFRICA – National Department of Health  
The Department of Health of the South African government is the department in charge 
of health issues with a view to improve the healthcare delivery system. 
As specifically regards medical devices, currently only electronic medical devices are 
regulated, therefore, medical devices other than these are not regulated in South Africa.  
No publicly available information with regard to the safety of MDs and In Vitro 
Diagnostics (IVDs) relevant for the European market has been found.   
 
Table 1. Sources of alerts, recalls & other relevant info (IMDRF members) 
 
Source: JRC MDTF, 2017. 
 
 
Member Alerts  Recalls  
Other safety related 
information 
Australia Alerts 
System for Australian Recall 
Actions 
SARA 
Incident Reporting and 
Investigation Scheme 
IRIS 
Database of Adverse Event 
Notifications 
DAEN 





Informes sobre produtos para 
saúde 
Canada 
Recalls and Safety Alerts 
Database 
 
Recalls and Safety Alerts 
Database 
Health Product Info Watch 
Canada Vigilance Adverse 
Reaction Online Database 
China N/A N/A N/A 
Japan 
"Yellow Letter" "Yellow Letter" 
Notices to revise the   
precautions 
"Blue Letter"  
MHLW Pharmaceuticals and MD 
Safety Information (JN only) 
Russia N/A N/A N/A 
Singapore 
Medical Device Alerts 
Product Recalls 
Dear Healthcare Professional 
Letters 
Product Safety Alerts 
Safety-related Product Label 
Amendments 
USA 
MedWatch - Safety 
Information and Adverse 
Event Reporting Program 
 
 
CDRH – Medical Device 
Recalls 
MAUDE Manufacture and User 
Facility Device Experience  
MedSun - Medical Product 
Safety Network 
19 
Table 2. Sources of alerts, recalls & other relevant info (Non-IMDRF members) 
 
Member Alerts Recalls 
Other safety related 
information 
Argentina 
Alerts and Recalls of 
Medical Devices 
Alerts and Recalls of Medical 
Devices 
Techno-vigilance program 
Mexico Alertas sanitaria   
Nigeria 
Recalls & Alerts Published 
by NAFDAC 




NCMDRC – The National 
Centre for MD Reporting 
NCMDRC – The National 
Centre for MD Reporting 
NCMDRC – The National Centre 
for MD Reporting 
S. Africa N/A N/A N/A 
 
Source: JRC MDTF, 2017. 
 
3.3 Quantitative analysis of extra-EU alerts and recalls  
Quantitative analysis  
In December 2013, in an attempt to provide a quantitative overview about the amount of 
alerts and recalls expected to be identified on a daily basis outside the EU, the JRC 
conducted a preliminary monitoring of the alerts and recalls occurred from January to 
November 2013 in the thirteen regions that were made the subject of this report 
(Chapter 2.2), with the exception of Singapore which became official member of the 
IMDRF on 15 September 201618. 
It is to be noted that Japan and Russia are not included in this activity because the 
information provided through their websites is in national language only and translation 
was not available at the time of the analysis.  
The main objective of the JRC was to provide an overview about the average number of 
safety measures (alerts/recalls) potentially affecting the EU and for which the presence 
on the European market would need to be verified.  
As showed in the table below (Table 4), on average, 23 alerts and/or recalls are expected 
to be daily published through the official webpages of the relevant regulators.  
The analysis also suggested that, in order for a daily monitoring system of extra EU 
alerts and recalls to be effective, the following issues will need to be preliminarily 
ascertained: 
 The product is a medical device or an in vitro diagnostics, 
 The product bears a "Conformité Européenne" (CE) marking, 
 The device is placed on the EU market, 
 The specific issue impacts the EU, 
 The device is available for sale in the EU, 
 The real manufacturer/authorised representative and its legal base in the EU, 
 Real nature of the action taken (alert, recall or other). 
 
                                           
18 http://www.imdrf.org/docs/imdrf/final/meetings/imdrf-meet-160913-brazil-meeting-outcome-statement.pdf.  
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Analysis of the EU relevance  
In a second phase, through a search into the European databank on Medical Devices 
(EUDAMED), the JRC verified whether the affected devices analysed were distributed in 
one or more countries within the EU market.  
In order to ensure the coverage of the different categories of devices existing on the 
market, the analysis took into account alerts and recalls relating to ten device types: 
Configurable MD systems 
1. Recall - PET Discovery 600 and Discovery 690 Systems - S.A 
2. Recall - Home Choice dialysis equipment - BRA 
3. Recall - Autopulse resuscitation system model 100 - BRA 
4. Recall - iPlan RT Dose - BRA 
5. Recall - Puritan Bennett 840 Series Ventilator - US 
6. Recall - Imaging system software, CardiacVX and CardiacVX Flow - S.A 
Implantable MD 
7. Alert - Journey Bi-Cruciate Stabil. (BCS) knee repl. system - femoral imp. - AUS 
8. Recall - Segmental System, Polyethylene Inserts - CAN 
9. Alert - Medtronic Mosaic Porcine Aortic Bioprosthesis - AUS 
Active Implantable MD 
10. Alert - Implantable infusion pumps - US 
11. Recall - Animas 2020 Infusion Insulin Pumps - US 
MD for dentistry 
12. Recall - SEAC Dental System - Model 2020 - CAN 
13. Recall - Toothbrush for kids - US 
MD for ophthalmology 
14. Recall - ACUVUE ADVANCE Brand Contact Lenses - US 
 
Brazil Canada Mexico Nigeria Saudi Arabia












day by month         
(22 wd) 
Jan 39 1 7 54 125 32 0 0 11 269 12
Feb 47 1 6 74 132 28 0 0 6 294 13
Mar 49 3 5 86 124 30 0 0 2 563 47
Apr 66 5 10 103 160 42 0 0 13 399 18
May 62 2 15 79 251 37 0 0 7 453 20
Jun 42 3 7 69 177 24 0 0 13 852 39
Jul 59 11 7 85 213 32 0 0 9 416 19
Aug 52 5 13 57 277 33 0 0 5 442 20
Sep 37 3 7 66 169 28 0 0 2 858 39
Oct 54 5 22 42 112 33 0 0 2 270 12
Nov 58 4 10 6 303 34 0 0 6 421 19
Dec




MD for respiratory/anaesthesia 
15. Recall - Compressor Mini - S.A. 
16. Recall - Puritan Bennett™ 840 ventilator - BRA 
17. Recall - Fabius Series Anesthesia Machines - US 
In vitro diagnostic devices 
18. Recall - Citrate Activated Partial Thromboplastin Time Cuvettes - AUS 
19. Alert - TRUEtrack blood glucose meters - CAN 
20. Recall - ABL90 FLEX Analyser - AUS 
21. Recall - Vitros Immunodiagn. Prod.s Anti-HBS Calibrator and Reagent Pack - CAN 
Surgical instruments 
22. Alert - Endo GIA Articulating™ 60-3.5mm Surgical Stapler Reloads - CAN 
23. Alert - 27G Sterile Cannula Packed in Amvisc and Amvisc Plus - US 
24. Recall - Hi- Torque connect guidewire - BRA 
25. Recall - Steris Fine Traction Device - CAN 
Single use/Sterile MD 
26. Recall - INSUPEN- Sensitive Needles - BRA 
27. Recall - Vented Spike with Clearlink - AUS 
28. Recall - Femoral Arterial and Venous Cannulae - S.A. 
Hospital equipment 
29. Recall - S3 and Secure II Medical/Surgical Beds. - S.A. 
30. Alert - Liko overhead lifts ceiling-mounted rail systems – AUS 
The analysis focused on the alerts and recalls occurred in five of the thirteen countries 
that were made the subject of the current report (See Chapter 2.2) and takes into 
consideration 30 safety measures (7 alerts / 23 recalls) adopted in the time frame May 
2013-January 2014. 
The five selected countries (Australia, Brazil, Canada, Saudi Arabia and United States) 
were chosen because their official webpages provide relevant information on alerts and 
recalls either in English or in a language easily understandable and translatable by the 
JRC staff working on this project. 
As the summary table below shows (Table 4), the analysis of the 30 safety measures 
carried out through EUDAMED provided information relevant to the EU, with different 
degrees of approximation, in 18 cases.  
This information helped identifying the Competent Authority/s that might be affected by 
the concerned safety issues occurred outside the EU. 
It is to be noted that, although the devices found in EUDAMED seem to be corresponding 
to the products affected by the alerts/recalls issued outside the EU, the information 
provided by EUDAMED is, in most cases, insufficient to ensure that they are exactly the 
same products. 
This question, along with the general issue regarding the development of an automated 
system for early detection of signals outside the EU, will be further explored under 




Table 4. Analysis of the EU relevance  
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Puritan Bennett 840 
Series Ventilator  
Configurable MD system INC-IE-14-01-000005 
DVC-IE-14-01-000022 
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3.4 Compilation of recalls and alerts occurring over a six week 
period 
As a completion of the quantitative analysis carried out in December 2013 and described 
under paragraph 3.3 of this report, in July 2016 the JRC conducted a scoping exercise 
collecting available recalls and alerts made available by selected non EU regulators from 
the 2nd of May 2016 to the 12th of June 2016 (6 weeks). 
For practical reasons, this exercise takes into account only the four regulators (US FDA, 
Health Canada, TGA Australia and Saudi Arabia SFDA) of which the official websites 
provide comparable information in English. 
This activity aims to provide a realistic picture regarding the nature of information that 
can be expected through a regular monitoring of the sources made available by non EU 
authorities. 
In this respect, the scoping exercise shows which device types are mainly affected by 
alerts and recalls, gives indications about the most frequent problems encountered and 
actions undertaken, and allows to compare all data in view of possible trending analysis. 
Moreover, US FDA website also provides information about the countries (including EU 
MS) where an alert or recall has occurred. 
This information allows appreciating the amount and kind of actions that would be 
needed, on a daily basis, to properly react to the relevant information coming from 
outside Europe.  
Nevertheless, the distribution list provided by the FDA authority only concerns those 
products for which an alert or recall has been taken in the United States.  
Therefore, in order to be able to ascertain whether the products affected by an alert or 
recall in all the countries (other than US) have been placed on the European territory, the 
EU competent authorities would need to explore and possibly identify additional methods 
or ways, such as systematic check into EUDAMED.  
The figures below provide a summary of the main findings relating to the collected data: 
 83 alerts/recalls per week (12 per day), on average, 
 10 Alerts,  
 486 Recalls, 
 201 alerts and recalls relevant for the EU, 
 42 IVDs and 454 non IVDs affected. 
Full information regarding the data collected through the scoping exercise is available in 
the table attached to this document (See Supplementary material). 
This table will serve as a basis for the EU CAs to further explore the actual usefulness of 
the analysed information, the most appropriate way to take advantage of it and possible 
technical solutions supporting its effective management for prompt reaction to/early 






3.5 IT tools for automated collection and analysis of alerts and 
recalls 
The large amount of data on alerts and recalls that are expected to be published on a 
daily basis shows that they cannot be treated manually due to excessive workload. 
Conversely, an automated system for collection and analysis of this information would be 
ideal to support prompt and accurate reaction to safety issues. 
In particular, a series of IT tools is needed to ensure that the relevant information is 
appropriately collected, checked, stored and translated. 
Therefore, it appears of utmost importance to start working on the development of key 
IT tools serving for: 
 Centralised collection of the information, 
 Targeted data mining throughout the identified sources/websites, 
 Appropriate entity check, 
 Automatic translation into English of retrieved alerts and recalls, 
 Effective display of all relevant information (i.e. through a dedicated webpage), e.g. 
on a weekly basis and including an effective archiving function. 
The figure below (Fig. 1) shows a schematic depiction of the IT infrastructure that would 
potentially support automated collection and analysis of extra EU alerts and recalls. 
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3.5.1 DG JRC's translation tool 
In order to ensure an effective use of the collected data on alerts and recalls, it is 
important that the relevant information, as provided through the analysed sources (See 
Chapter 3), is appropriately translated from the local languages to English. In this 
respect, the JRC identified the "Optima News Translation System" (ONTS) as a potentially 
ideal solution.  
The "Optima News Translation System" (ONTS) is an application embedded into the 
Europe Media Monitor19 (EMM) system and was developed in-house by researchers of the 
JRC's Directorate I "Competences". Based on the open source software MOSES20, the 
ONTS translation engine translates news from 16 languages21 into English using 
statistical methods and large amounts of data to identify the correct translation of each 
phrase and to link them together in a comprehensive English sentence.  
Although acting on a unidirectional basis, the ONTS system is able to cover a very wide 
range of languages (See Fig. 2).  
Moreover, beside the languages already covered, the JRC's tool may, in the future, also 
allow translations from additional languages.  
This would be particularly relevant for languages like Russian and Japanese referring to 
two countries which are members of the International Medical Device Regulators Forum 
(IMDRF) and represent very important markets of medical devices and, therefore, are 
precious sources of safety information. 
Figure 2. JRC's ONTS translation system  
 
                                           
19 EMM is a live media monitoring system which gathers around 150,000 news articles every day from over 
3750 internet news websites from around the world in over 62 different languages. 
https://ec.europa.eu/jrc/en/scientific-tool/europe-media-monitor-newsbrief. 
20 Moses is a statistical machine translation system that allows automatically training translation models for any 
language pair. 
https://ec.europa.eu/jrc/en/scientific-tool/europe-media-monitor-newsbrief. 
21 De (EMM native technology), It (EMM native technology), Es (EMM native technology), Fr (EMM native 
technology), Fa (EMM native technology), Pt (EMM native technology), Cs (EMM native technology), Sa (EMM 
native technology), Pl (EMM native technology), Ru (EMM native technology), Sv (EMM native technology), Nl 
(EMM native technology), Lt (EMM native technology), Lv (EMM native technology), Ar (EMM native technology 
+ language weaver), Zh (EMM language weaver). 
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4 Supplementary material 
The supplementary material to this report (electronic form) provides a compilation of 
information relating to alerts and recalls occurred in Australia, Canada, United States and 
Saudi Arabia and published through the websites of their medical devices agencies from 
the 1st of May to the 11th of June (6 weeks). 
This data collection covers four of the regulatory authorities (Australian TGA, Health 
Canada, US FDA, Saudi Arabian SFDA) included in the analysis under chapter 3 of this 
report mainly due to the fact that they provide information in English.  
The data collected regard the type of safety measures (alert or recall), the specific device 
concerned (trade product name), and the related manufacturer, the description of the 
background/reason and of the actions recommended. 
Information about the worldwide distribution of products, which is particularly important 
in order to appreciate whether a safety issue concerns the Union territory, is provided 
only by the US FDA. 
This information is not provided by any other regulatory authority, therefore, in order to 
check if an extra EU safety measure affects the Union territory, EUDAMED appears to be 
the most appropriate means.  
However, due to the gaps and shortcomings of the current EUDAMED (See EUDAMED 
Evaluation Report22), this would be really effective only once the future European 
centralised databank will be fully operational.  
In this respect, a manual searching test conducted by JRC in 2013 (See paragraph 3.3) 
showed that, in spite of the workload needed to search information into the current 
EUDAMED, the results obtained were not fully satisfactory mainly due to lack of 
information.  
For this reason, the Annex does not contain data related to EUDAMED research although 


















                                           
22 http://ec.europa.eu/DocsRoom/documents/12981/attachments/1/translations. 
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5 Conclusions  
This report provides key information on additional data sources on alerts, recalls and 
other safety relevant information which have not been systematically used until now.  
The appropriate management of this information would therefore be crucial for effective 
signal detection by regulators, both in the EU and worldwide.  
To this aim, starting from the review of the existing sources of information, the document 
gives input and suggestions towards: 
(1) Improved data set,  
(2) Appropriate technical tools,  
(3) Automated ways for EU relevance verification and 
(4) Practical working procedure for management of the information collected.  
 
i) Data sets and terminology 
The report shows that a large amount of extra EU data on alerts and recalls and other 
relevant safety information is available.  
Although very promising in view of the data richness, the possible systematic collection 
and use of this information is hampered by variations in terminology used by the 
different regulators.  
In particular, it has been noted that terms are not always used to identify the same 
concepts (e.g. “alert” is used also to identify a “recall” and vice versa).  
Alignment and harmonisation of this terminology would be supportive of the collection of 
this information but also its exchange and joint analysis by various regulators. 
Moreover, the way how data are presented is very heterogeneous and fragmented, 
ranging from ad hoc and complete databases (e.g. on alerts, recalls or other safety 
communications) to simple lists of information of different nature (e.g. alerts, recalls, 
safety notices, etc…). 
These divergences could represent an obstacle for effective automated collection and 
analysis of data. 
Recommendations:  
(1) We recommend exploring the opportunity for an international clarification and 
harmonisation of the terminology relating to safety information on medical 
devices.  
(2) For this purpose, the issue could be brought to the attention of the IMDRF. 
 
ii) Technical tools 
The report outlines the main technical tools that would need to be developed in support 
of an effective management of the existing safety information.  
Indeed, the nature, amount and way how the safety information is daily published and 
displayed through the analysed extra EU websites pose a series of technical issues.  
In this respect, the report suggests a potential IT infrastructure for automated collection 
and analysis of data which highlights the main tools and solutions to be set up for 
identifying, collecting, checking, translating and displaying the relevant information. 
 Recommendations: 
 We recommend developing an integrated IT infrastructure supporting automated 
collection and preliminary analysis of data.  
 This should mainly include IT programmes allowing for entity check and data 
mining, a webpage for displaying information and a translation tool. 
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iii) EU relevance verification 
A - The report shows that, in order to ensure effective signal detection, it will be 
important to set a process able to rapidly determine whether a recall or alert occurred 
outside the EU is relevant for the Union market.  
B - In addition, it is important to highlight that relevance does not necessarily imply 
presence of the concerned product on the Union territory. Indeed, safety actions 
regarding products not on the EU market could also reveal risks and support early 
vigilance "pattern recognition" (i.e. correlations between use of devices and adverse 
health effects), they also need to be systematically identified and analysed. 
Recommendations:  
(1) We recommend using the future EUDAMED as the key tool to provide information 
about the presence of the product on the EU.  
(2) We recommend establishing a structured dialogue between all stakeholders and 
CAs for the early detection of potential risks relating to products not placed on the 
EU. 
 
iv) Working procedure  
An effective management of the existing extra EU safety information would require a 
coordinated approach at European level to ensure full share and coordinated treatment of 
the available data.  
Recommendations: 
(1) We recommend setting up a practical procedure for the systematic management 
of alerts, recalls and other relevant safety information.  
(2) This procedure should allow for prompt analysis and coordinated reaction to safety 
problems affecting the EU territory and could be put in place by MS CAs and EC in 
the framework of the EU Vigilance Medical Device Expert Group (MDEG), e.g. 
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